Preoperative assessment of HER-2/neu status in breast carcinoma: The role of quantitative real-time PCR on core-biopsy specimens

Gynecologic Oncology

Volumn 116, Issue 2, 2010, Pages 234-239

  Susini, Tommaso ^a   Bussani, Cecilia ^a   Marini, Giulia ^a   Nori, Jacopo ^b   Olivieri, Simone ^a   Molino, Cecilia ^a   Bianchi, Simonetta ^a   Vezzosi, Vania ^a   Paglierani, Milena ^a   Giachi, Massimo ^a   Borrani, Elena ^a   Scarselli, Gianfranco ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Breast carcinoma; Core biopsy; HER 2 neu; Quantitative real time polymerase chain reaction (qRT PCR); Targeted treatments

Indexed keywords

ARTICLE; BIOPSY; BREAST CARCINOMA; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE NEU; PREDICTIVE VALIDITY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

BIOPSY; BREAST NEOPLASMS; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 73949142804     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.10.067     Document Type: Article

References (41)

1. Fisher B. From Halsted to prevention and beyond: advances in the management of breast cancer during the twentieth century. Eur. J. Cancer 35 (1999) 1963-1973
2. Goldhirsch A., Wood W.C., Gelber R.D., Coates A.S., Thürlimann B., and Senn H.J. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann. Oncol. 18 (2007) 1133-1144
3. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
4. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 (1989) 707-712
5. Gusterson B.A., Gelber R.D., Goldhirsch A., Price K.N., Säve-Söderborgh J., Anbazhagan R., et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J. Clin. Oncol. 10 (1992) 1049-1056
6. Goldenberg M.M. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin. Ther. 21 (1999) 309-318
7. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344 (2001) 783-792
8. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353 (2005) 1659-1672
9. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer Jr. C.E., Davidson N.E., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353 (2005) 1673-1684
10. Slamon D., Eiermann W., Robert N., Pienkowski T., Martin M., and Pawlicki M. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study[abstract 1]. Breast Cancer Res. Treat. 94 Suppl 1 (2005) S5
11. Joensuu H., Kellokumpu-Lehtinen P.L., Bono P., Alanko T., Kataja V., Asola R., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 354 (2006) 809-820
12. Buzdar A.U., Ibrahim N.K., Francis D., Booser D.J., Thomas E.S., Theriault R.L., et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J. Clin. Oncol. 23 (2005) 3676-3685
13. Arnould L., Arveux P., Couturier J., Gelly-Marty M., Loustalot C., Ettore F., et al. Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification. Clin. Cancer Res. 13 (2007) 6404-6409
14. Esteva F.J., Wang J., Lin F., Mejia J.A., Yan K., Altundag K., et al. CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer. Breast Cancer Res. 9 (2007) R87
15. Dawood S., Gonzalez-Angulo A.M., Peintinger F., Broglio K., Symmans W.F., Kau S.W., et al. Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience. Cancer 110 (2007) 1195-1200
16. Limentani S.A., Brufsky A.M., Erban J.K., Jahanzeb M., and Lewis D. Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer. J. Clin. Oncol. 25 (2007) 1232-1238
17. Buzdar A.U., Valero V., Ibrahim N.K., Francis D., Broglio K.R., Theriault R.L., et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin. Cancer Res. 13 (2007) 228-233
18. Lazaridis G., Pentheroudakis G., and Pavlidis N. Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: accumulating evidence of efficacy, synergy and safety. Crit. Rev. Oncol. Hematol. 66 (2008) 31-41
19. Paluch-Shimon S., Wolf I., Goldberg H., Evron E., Papa M.Z., Shabtai M., et al. High efficacy of pre-operative trastuzumab combined with paclitaxel following doxorubicin and cyclophosphamide in operable breast cancer. Acta Oncol. 47 (2008) 1564-1569
20. Coudert B.P., Largillier R., Arnould L., Chollet P., Campone M., Coeffic D., et al. Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial. J. Clin. Oncol. 25 (2007) 2678-2684
21. Pauletti G., Dandekar S., Rong H., Ramos L., Peng H., Seshadri R., et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J. Clin. Oncol. 18 (2000) 3651-3664
22. Bast Jr. R.C., Ravdin P., Hayes D.F., Bates S., Fritsche Jr. H., Jessup J.M., et al. 000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol. 19 (2001) 1865-1878
23. Hanna W. Testing for HER2 status. Oncology 61 Suppl 2 (2001) 22-30
24. Onody P., Bertrand F., Muzeau F., Bièche I., and Lidereau R. Fluorescence in situ hybridization and immunohistochemical assays for HER-2/neu status determination: application to node-negative breast cancer. Arch. Pathol. Lab. Med. 125 (2001) 746-750
25. Tubbs R.R., Pettay J.D., Roche P.C., Stoler M.H., Jenkins R.B., and Grogan T.M. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J. Clin. Oncol. 19 (2001) 2714-2721
26. Paik S., Bryant J., Tan-Chiu E., Romond E., Hiller W., Park K., et al. Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J. Natl. Cancer Inst. 94 (2002) 852-854
27. Roche P.C., Suman V.J., Jenkins R.B., Davidson N.E., Martino S., Kaufman P.A., et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J. Natl. Cancer Inst. 94 (2002) 855-857
28. de Cremoux P., Martin E.C., Vincent-Salomon A., Dieras V., Barbaroux C., Liva S., et al. Quantitative PCR analysis of c-erb B-2 (HER2/neu) gene amplification and comparison with p185(HER2/neu) protein expression in breast cancer drill biopsies. Int. J. Cancer 83 (1999) 157-161
29. Schlemmer B.O., Sorensen B.S., Overgaard J., Olsen K.E., Gjerdrum L.M., and Nexo E. Quantitative PCR-new diagnostic tool for quantifying specific mRNA and DNA molecules: HER2/neu DNA quantification with LightCycler real-time PCR in comparison with immunohistochemistry and fluorescence in situ hybridization. Scand. J. Clin. Lab. Invest. 64 (2004) 511-522
30. Vinatzer U., Dampier B., Streubel B., Pacher M., Seewald M.J., Stratowa C., et al. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization. Clin. Cancer Res. 11 (2005) 8348-8357
31. Kulka J., Tôkés A.M., Kaposi-Novák P., Udvarhelyi N., Keller A., and Schaff Z. Detection of HER-2/neu gene amplification in breast carcinomas using quantitative real-time PCR-a comparison with immunohistochemical and FISH results. Pathol. Oncol. Res. 12 (2006) 197-204
32. Jacobs T.W., Gown A.M., Yaziji H., Barnes M.J., and Schnitt S.J. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J. Clin. Oncol. 17 (1999) 1983-1987
33. Moore J.G., To V., Patel S.J., and Sneige N. HER-2/neu gene amplification in breast imprint cytology analyzed by fluorescence in situ hybridization: direct comparison with companion tissue sections. Diagn. Cytopathol. 23 (2000) 299-302
34. Rilke F., Colnaghi M.I., Cascinelli N., Andreola S., Baldini M.T., Bufalino R., et al. Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int. J. Cancer 49 (1991) 44-49
35. Zanetti-Dällenbach R., Vuaroqueaux V., Wight E., Labuhn M., Singer G., Urban P., et al. Comparison of gene expression profiles in core biopsies and corresponding surgical breast cancer samples. Breast Cancer Res. 8 (2006) R51
36. Merkelbach-Bruse S., Wardelmann E., Behrens P., Losen I., Buettner R., and Friedrichs N. Current diagnostic methods of HER-2/neu detection in breast cancer with special regard to real-time PCR. Am. J. Surg. Pathol. 27 (2003) 1565-1570
37. Ntoulia M., Kaklamanis L., Valavanis C., Kafousi M., Stathopoulos E., Arapantoni P., et al. HER-2 DNA quantification of paraffin-embedded breast carcinomas with LightCycler real-time PCR in comparison to immunohistochemistry and chromogenic in situ hybridization. Clin. Biochem. 39 (2006) 942-946
38. Bilous M., Ades C., Armes J., Bishop J., Brown R., Cooke B., et al. Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study. Breast 12 (2003) 92-98
39. Elkin E.B., Weinstein M.C., Winer E.P., Kuntz K.M., Schnitt S.J., and Weeks J.C. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J. Clin. Oncol. 22 (2004) 854-863
40. Gjerdrum L.M., Sorensen B.S., Kjeldsen E., Sorensen F.B., Nexo E., and Hamilton-Dutoit S. Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for HER-2/neu analysis. J. Mol. Diagn. 6 (2004) 42-51
41. Dendukuri N., Khetani K., McIsaac M., and Brophy J. Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis. CMAJ 176 (2007) 1429-1434